Bharat Biotech’s Covaxin received nod from Subject Expert Committee (SEC) on Tuesday who further proffered positive recommendation to DCGI for the use of Covaxin in 2-18 years age group. Bharat Biotech has earlier submitted data from clinical trials to the Central Drugs Standard Control Organisation (CDSCO) for its verification and subsequent approval for emergency use authorisation (EUA) for the jab at the beginning of this month.